Sanofi discusses $275 per Actelion share for potential deal - Bloomberg

Dec 15 (Reuters) - French drugmaker Sanofi is in

advanced talks to buy Actelion Ltd and is discussing a

price of about $275 per share for the Swiss drugmaker, Bloomberg

reported on Thursday.

Read more